TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026)

TerrAscend's (TSNDF) quarterly Total Non-Current Liabilities came in at $390.5 million in Q1 2026, up 8.97% year-on-year from $358.3 million in Q1 2025, and up 3.18% on a QoQ basis from $378.4 million in Q4 2025.

TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

TerrAscend (TSNDF) has 7 years of Total Non-Current Liabilities data on file, last reported at $390.5 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 8.97% year-over-year to $390.5 million in Q1 2026; TTM through Mar 2026 was $390.5 million, a 8.97% increase from a year earlier, with the FY2025 full-year figure at $378.4 million, up 11.51% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $390.5 million, up from $378.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for TSNDF reached as high as $390.5 million in Q1 2026 and fell as low as $218.8 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $319.3 million across 5 years, with a median of $339.4 million in 2024.
  • Across the five-year window, Total Non-Current Liabilities slumped 32.16% in 2023 and surged 59.75% in 2025, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $242.5 million in 2022, then decreased by 9.79% to $218.8 million in 2023, then soared by 55.12% to $339.4 million in 2024, then gained by 11.51% to $378.4 million in 2025, then advanced by 3.18% to $390.5 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $390.5 million in Q1 2026, $378.4 million in Q4 2025, and $383.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 TerrAscend 160.44 Mn 162.98 Mn 34.60 Mn 390.48 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 390.48 Mn
Dec 31, 2025 378.43 Mn
Sep 30, 2025 383.47 Mn
Jun 30, 2025 361.96 Mn
Mar 31, 2025 358.34 Mn
Dec 31, 2024 339.37 Mn
Sep 30, 2024 371.36 Mn
Jun 30, 2024 356.64 Mn
Mar 31, 2024 224.31 Mn
Dec 31, 2023 218.78 Mn
Sep 30, 2023 303.50 Mn
Jun 30, 2023 292.66 Mn
Mar 31, 2023 246.20 Mn
Dec 31, 2022 242.51 Mn
Sep 30, 2022 274.32 Mn
Jun 30, 2022 323.25 Mn
Mar 31, 2022 362.90 Mn
Dec 31, 2021 286.79 Mn
Dec 31, 2020 -132.26 Mn